W. Michael Flanagan
CIK: 0001841990
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (32 total)
- Sep 18, 2026RNA
Atrium Therapeutics, Inc.
Tax Payment(F)Direct22.8K shares at avg. $8.95$204K - Feb 27, 2026RNA
Atrium Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20K shares- - Feb 27, 2026RNAM
Avidity Biosciences, Inc.
Disposition(D)Direct150.4K shares- - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct4K shares at avg. $72.45$288K - Jan 21, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.6K shares at avg. $72.45$185K - Jan 7, 2026RNA
Avidity Biosciences, Inc.
Sale(S)Direct2.4K shares at avg. $72.23$171K - Dec 17, 2025RNA
Avidity Biosciences, Inc.
Tax Payment(F)Direct13.7K shares at avg. $71.87$984K - Dec 17, 2025RNA
Avidity Biosciences, Inc.
Award(A)Direct27.5K shares- - Sep 11, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct20K shares at avg. $38.94$779K - Sep 11, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct20K shares at avg. $14.22$284K - Jun 11, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct20K shares at avg. $32.88$658K - Jun 11, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct20K shares at avg. $14.22$284K - Mar 20, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct11.8K shares at avg. $31.06$366K - Mar 11, 2025RNA
Avidity Biosciences, Inc.
Exercise(M)Direct20K shares at avg. $14.22$284K - Mar 11, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct20K shares at avg. $30.13$603K - Jan 21, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct3.9K shares at avg. $28.60$110K - Jan 21, 2025RNA
Avidity Biosciences, Inc.
Sale(S)Direct1.8K shares at avg. $28.59$52K - Jan 6, 2025RNA
Avidity Biosciences, Inc.
Award(A)Direct25K shares- - Dec 18, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct12.7K shares at avg. $32.66$416K - Dec 11, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct24K shares at avg. $35.77$858K - Dec 11, 2024RNA
Avidity Biosciences, Inc.
Exercise(M)Direct24K shares at avg. $22.47$539K - Oct 1, 2024RNA
Avidity Biosciences, Inc.
Exercise(M)Direct62.5K shares at avg. $26.75$1.7M - Oct 1, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct62.5K shares at avg. $47.62$3.0M - Sep 23, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct13.2K shares at avg. $44.00$579K - Sep 23, 2024RNA
Avidity Biosciences, Inc.
Sale(S)Direct11.8K shares at avg. $43.89$520K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 18, 2026 |  RNA Atrium Therapeutics, Inc. | Tax Payment(F) | 22,812 | $8.95 | $204,167 | Direct |
| Feb 27, 2026 | RNA Atrium Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Feb 27, 2026 |  RNAM Avidity Biosciences, Inc. | Disposition(D) | 150,365 | - | $0 | Direct |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 3,976 | $72.45 | $288,061 | Direct |
| Jan 21, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,558 | $72.45 | $185,327 | Direct |
| Jan 7, 2026 | RNA Avidity Biosciences, Inc. | Sale(S) | 2,373 | $72.23 | $171,402 | Direct |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | Tax Payment(F) | 13,695 | $71.87 | $984,260 | Direct |
| Dec 17, 2025 | RNA Avidity Biosciences, Inc. | Award(A) | 27,500 | - | - | Direct |
| Sep 11, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 20,000 | $38.94 | $778,702 | Direct |
| Sep 11, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 20,000 | $14.22 | $284,400 | Direct |
| Jun 11, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 20,000 | $32.88 | $657,694 | Direct |
| Jun 11, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 20,000 | $14.22 | $284,400 | Direct |
| Mar 20, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 11,780 | $31.06 | $365,868 | Direct |
| Mar 11, 2025 | RNA Avidity Biosciences, Inc. | Exercise(M) | 20,000 | $14.22 | $284,400 | Direct |
| Mar 11, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 20,000 | $30.13 | $602,614 | Direct |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 3,860 | $28.60 | $110,383 | Direct |
| Jan 21, 2025 | RNA Avidity Biosciences, Inc. | Sale(S) | 1,812 | $28.59 | $51,809 | Direct |
| Jan 6, 2025 | RNA Avidity Biosciences, Inc. | Award(A) | 25,000 | - | $0 | Direct |
| Dec 18, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 12,742 | $32.66 | $416,154 | Direct |
| Dec 11, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 24,000 | $35.77 | $858,401 | Direct |
| Dec 11, 2024 | RNA Avidity Biosciences, Inc. | Exercise(M) | 24,000 | $22.47 | $539,280 | Direct |
| Oct 1, 2024 | RNA Avidity Biosciences, Inc. | Exercise(M) | 62,500 | $26.75 | $1,671,875 | Direct |
| Oct 1, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 62,500 | $47.62 | $2,976,113 | Direct |
| Sep 23, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 13,153 | $44.00 | $578,737 | Direct |
| Sep 23, 2024 | RNA Avidity Biosciences, Inc. | Sale(S) | 11,847 | $43.89 | $519,996 | Direct |
1-25 of 32 transactions
About Flanagan W. Michael
Flanagan W. Michael (SEC CIK 0001841990) files insider reports with the SEC as Director of Atrium Therapeutics, Inc. (RNA) and Chief Scientific Officer of Avidity Biosciences, Inc. (RNAM).
Signal8 holds 18 ownership filings by Flanagan W. Michael (1 Form 3, 17 Form 4), filed between Sep 13, 2024 and Sep 22, 2026. Those filings report 32 transactions, from Sep 11, 2024 to Sep 18, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Flanagan W. Michael's filings is in SAN DIEGO, CA.
Recent filings by Flanagan W. Michael
- Sep 18, 2026: Tax withholding of RNA shares (Form 4, code F).
- Feb 27, 2026: Grant or award of RNA derivative securities (Form 4, code A).
- Feb 27, 2026: Disposition to issuer transaction of RNAM shares (Form 4, code D).
- Jan 21, 2026: Open-market sales of RNA shares (2 lines, Form 4, code S).
- Jan 7, 2026: Open-market sale of RNA shares (Form 4, code S).
Other insiders filing for Atrium Therapeutics, Inc. (RNA)
- Younis Husam, Chief Scientific Officer
- Hughes Steven George, Chief Medical Officer
- Boyce Sarah, Director
- Kenney Stephanie
- Gallagher Kathleen P.
- Winslow Brendan R., Chief Financial Officer